FDA Advisory Committee Sees Benefits of CAR-T Leukemia Therapy

Drug Industry Daily
A A
An FDA advisory committee voted unanimously Wednesday in favor of the risk-benefit profile for Novartis’ BLA for an innovative new cancer therapy.

To View This Article:

Login

Subscribe To Drug Industry Daily